Red Light Therapy & Alzheimer’s Risk: The Evidence

ByRohan Smith

Red Light Therapy: A Potential Solution for Reducing Alzheimer's Risk

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer

Red light therapy (photobiomodulation) is an emerging experimental approach being investigated for its potential to support brain health in individuals at risk of Alzheimer’s disease. Preclinical and early human studies suggest it may enhance mitochondrial ATP production, reduce beta-amyloid burden, and modulate neuroinflammation. However, evidence remains preliminary, and photobiomodulation is not a proven treatment or preventive strategy for Alzheimer’s disease (1-3).

At a Glance

  • Photobiomodulation uses red and near-infrared wavelengths (typically 600-1100 nm) to stimulate cytochrome c oxidase in neuronal mitochondria, potentially enhancing ATP production (10,11).
  • Preclinical models by researchers including Purushothuman et al. and Lu et al. have demonstrated reductions in beta-amyloid plaque burden following near-infrared light exposure (18,19).
  • Saltmarche et al. (2017) reported modest cognitive improvements in a small group of Alzheimer’s patients receiving transcranial photobiomodulation (16).
  • Chronic neuroinflammation and oxidative stress, mediated by pathways involving NF-kB and reactive oxygen species (ROS), are key targets of photobiomodulation research (12,13).
  • Red light therapy remains experimental and is not endorsed by the Alzheimer’s Association or the Therapeutic Goods Administration (TGA) as a disease-modifying intervention.

Understanding Alzheimer’s Disease

Alzheimer’s disease is a progressive neurodegenerative condition characterised by the accumulation of beta-amyloid plaques and hyperphosphorylated tau protein tangles within the brain. These abnormal protein aggregates, first described by Alois Alzheimer in 1906, interfere with neuronal communication, contribute to synaptic dysfunction, and ultimately lead to memory impairment and cognitive decline (4-6).

Although the exact cause of Alzheimer’s disease remains incompletely understood, the National Institute on Aging (NIA) and the Alzheimer’s Association (NIA-AA) have identified multiple contributing factors, including age-related changes, genetic susceptibility (notably the APOE e4 allele), metabolic dysfunction, chronic inflammation, and oxidative stress. These overlapping processes create a complex disease pathway rather than a single causative trigger (7-9).

Contributing Factor Biological Mechanism Key References
Beta-amyloid accumulation Plaque formation disrupting synaptic signalling Querfurth & LaFerla, 2010 (4)
Tau hyperphosphorylation Neurofibrillary tangles impairing axonal transport De Strooper & Karran, 2016 (5)
Mitochondrial dysfunction Reduced ATP production and increased ROS Swerdlow, 2018 (8)
Neuroinflammation Microglial activation and pro-inflammatory cytokine release Heneka et al., 2015 (7)
Metabolic impairment Cerebral glucose hypometabolism Cunnane et al., 2020 (9)

Red Light Therapy: A Novel Approach to Neurodegenerative Research

Photobiomodulation involves exposure to low-level red (600-700 nm) or near-infrared (700-1100 nm) light at specific therapeutic wavelengths. This form of low-level light therapy (LLLT), as described by Michael Hamblin of Harvard Medical School and Massachusetts General Hospital, is designed to stimulate cellular processes involved in energy production and tissue repair. In neurological research, attention has focused on its potential effects on brain cells affected by neurodegenerative disease processes (1,3).

In the context of Alzheimer’s disease, red light therapy is being explored as an adjunctive strategy aimed at supporting cellular resilience rather than as a standalone treatment.

How Red Light Therapy Works: Mitochondrial and Cellular Mechanisms

Cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain) is the primary photoacceptor for red and near-infrared light. Adequate mitochondrial function is essential for neuronal health, synaptic activity, and cellular repair mechanisms, as demonstrated by Rojas and Gonzalez-Lima at the University of Texas at Austin (10,11).

By influencing cytochrome c oxidase activity, red light therapy may enhance adenosine triphosphate (ATP) production and improve cellular energy availability. In addition, photobiomodulation has been shown to modulate oxidative stress markers including reactive oxygen species (ROS) and inflammatory signalling pathways such as NF-kB, both of which are implicated in neurodegenerative disease progression (12,13).

Chronic neuroinflammation and oxidative damage are recognised contributors to neuronal injury in Alzheimer’s disease. Interventions that influence these pathways are therefore of interest in research aimed at slowing functional decline and are frequently explored in the context of chronic fatigue and neuroimmune conditions (14).

Evidence Supporting Red Light Therapy in Alzheimer’s Research

1. Cognitive Function

Berman et al. (2017) demonstrated that transcranial photobiomodulation may improve cognitive performance in healthy young adults, while Saltmarche et al. (2017) reported modest improvements in certain cognitive domains among individuals with mild cognitive impairment and dementia. These findings are preliminary and based on small study populations, but they suggest a possible role for photobiomodulation in cognitive support (15-17).

2. Beta-Amyloid Accumulation

Lu et al. (2017) demonstrated reductions in amyloid-beta levels in an Alzheimer’s disease mouse model following near-infrared light exposure. Purushothuman et al. (2014) similarly showed that photobiomodulation may mitigate amyloid-beta-induced neurotoxicity in primary hippocampal neurons. These findings suggest that photobiomodulation may influence protein clearance pathways involved in plaque accumulation, although translation to human outcomes remains under investigation (18,19).

3. Neuroprotective Effects

Mohammed et al. (2017) reported that photobiomodulation may support neuronal survival in neurodegeneration models. Synaptic plasticity, mediated by brain-derived neurotrophic factor (BDNF) and other neurotrophins, refers to the brain’s ability to adapt and reorganise neural connections, a function that is progressively impaired in Alzheimer’s disease (20,21).

4. Proposed Mechanisms

Mechanism Target Proposed Effect
Mitochondrial modulation Cytochrome c oxidase (Complex IV) Enhanced ATP synthesis
Oxidative stress reduction ROS, superoxide dismutase (SOD) Decreased oxidative neuronal damage
Anti-inflammatory regulation NF-kB pathway, TNF-alpha, IL-1beta Reduced microglial activation
Neuronal signalling support BDNF, synaptic plasticity Improved neural connectivity

The Path Forward for Photobiomodulation Research

Larger randomised controlled trials (RCTs) are needed to establish optimal dosing parameters, treatment duration, and clinical efficacy of transcranial photobiomodulation for Alzheimer’s disease. Current evidence, while promising in preclinical settings, has not yet met the evidentiary threshold required by bodies such as the Therapeutic Goods Administration (TGA) or the U.S. Food and Drug Administration (FDA) for clinical endorsement.

Optimising brain health requires a comprehensive approach that considers metabolic health, inflammation, nutrient status, sleep, and lifestyle factors. Functional medicine approaches focus on identifying contributing imbalances and supporting overall physiological resilience through personalised strategies, including assessment of the gut-brain axis.

Next Steps

  1. Assess your cognitive health: If you are experiencing cognitive concerns or wish to take a proactive approach to long-term brain health, a personalised assessment may help identify contributing factors.
  2. Address foundational drivers: Evidence-informed lifestyle and nutritional strategies — including metabolic health, inflammation management, sleep quality, and nutrient status — form the cornerstone of brain health support.
  3. Work with a qualified practitioner: Working with a qualified healthcare practitioner ensures that emerging therapies such as photobiomodulation are considered appropriately and safely within a broader care framework, such as a functional medicine approach to brain health.

Frequently Asked Questions

Can red light therapy prevent or treat Alzheimer’s disease?
No. Red light therapy is not a proven preventive or treatment for Alzheimer’s disease. Current research is preliminary and largely experimental. Photobiomodulation is being explored as a supportive, adjunctive strategy that may influence biological processes involved in neurodegeneration, rather than as a disease-modifying therapy.
Who might be most interested in red light therapy research for brain health?
Research interest has primarily focused on individuals with mild cognitive impairment or those at increased risk of neurodegenerative decline. However, potential relevance appears to depend on underlying factors such as mitochondrial dysfunction, oxidative stress, and neuroinflammation, rather than diagnosis alone.
Is red light therapy safe for brain health applications?
Red light therapy is generally considered low risk when used within researched parameters, but clinical standards for neurological use are still evolving. It should not be undertaken without appropriate guidance, particularly in individuals with neurological conditions or complex medical histories.

Key Insights

  • Alzheimer’s disease involves complex, multi-factorial processes including mitochondrial dysfunction, inflammation, and oxidative stress
  • Red light therapy (photobiomodulation) is being investigated for its potential to support cellular energy production and neuroprotective pathways via cytochrome c oxidase stimulation
  • Human evidence remains limited, with current findings from researchers such as Saltmarche et al. and Berman et al. considered preliminary and exploratory
  • Photobiomodulation is best viewed as an adjunctive, experimental approach rather than a preventive or therapeutic intervention
  • Long-term brain health is best supported through a comprehensive strategy addressing metabolic health, inflammation, sleep, nutrition, and lifestyle factors

Citable Takeaways

  1. Photobiomodulation targets cytochrome c oxidase (Complex IV) to enhance mitochondrial ATP production in neurons, according to Rojas and Gonzalez-Lima (2011) (10).
  2. Lu et al. (2017) demonstrated reduced amyloid-beta levels in an Alzheimer’s disease mouse model following near-infrared light exposure at approximately 670 nm (18).
  3. Saltmarche et al. (2017) reported significant cognitive improvement in a small cohort of Alzheimer’s patients receiving transcranial photobiomodulation over 12 weeks (16).
  4. Hamblin (2017) described photobiomodulation’s anti-inflammatory effects as operating through modulation of NF-kB signalling, reducing pro-inflammatory cytokines including TNF-alpha and IL-1beta (12).
  5. The NIA-AA Research Framework (Jack et al., 2018) defines Alzheimer’s disease biologically through biomarkers including beta-amyloid, phosphorylated tau, and neurodegeneration (6).
  6. Swerdlow (2018) proposed the mitochondrial cascade hypothesis, suggesting that mitochondrial dysfunction may be an upstream driver of Alzheimer’s pathology rather than a downstream consequence (8).

Take a Proactive Approach to Brain Health

If you are concerned about cognitive health or want to understand the metabolic and inflammatory factors that may influence long-term brain function, a personalised functional medicine assessment can help. At Elemental Health and Nutrition, we focus on identifying root contributors and building a comprehensive, evidence-informed strategy for neurological resilience.

Book an Appointment

References

  1. Hamblin MR. Photobiomodulation for the treatment of Alzheimer’s disease: is it time to move forward? J Alzheimers Dis. 2016;54(1):1-3. https://doi.org/10.3233/JAD-160460
  2. Caldieraro MA, Cassano P. Transcranial photobiomodulation for neuropsychiatric disorders: a systematic review. Psychiatr Clin North Am. 2019 Dec;42(4):669-686. https://doi.org/10.1016/j.psc.2019.07.005
  3. Salehpour F et al. Brain photobiomodulation therapy: a narrative review. Mol Neurobiol. 2018 Nov;55(11):8249-8267. https://doi.org/10.1007/s12035-018-0955-8
  4. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010 Jan 28;362(4):329-44. https://doi.org/10.1056/NEJMra0909142
  5. De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016 Feb 11;164(4):603-15. https://doi.org/10.1016/j.cell.2015.12.056
  6. Jack CR Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535-562. https://doi.org/10.1016/j.jalz.2018.02.018
  7. Heneka MT et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015 Apr;14(4):388-405. https://doi.org/10.1016/S1474-4422(15)70016-5
  8. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis. 2018;62(3):1403-1438. https://doi.org/10.3233/JAD-170585
  9. Cunnane SC et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrients. 2020 Jan 22;12(1):255. https://doi.org/10.3390/nu12010255
  10. Rojas JC, Gonzalez-Lima F. Low-level light therapy of the brain: from bench to bedside. Front Neurosci. 2011 Jun 7;5:74. https://doi.org/10.3389/fnins.2011.00074
  11. Cardoso SM et al. Mitochondrial dysfunction in Alzheimer’s disease: a role for amyloid-beta peptide. Neurochem Res. 2016;41(5):1023-1034. https://doi.org/10.1007/s11064-016-1822-3
  12. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. https://doi.org/10.3934/biophy.2017.3.337
  13. Chung H et al. The nuts and bolts of low-level light therapy. Ann Biomed Eng. 2012 Feb;40(2):516-33. https://doi.org/10.1007/s10439-011-0454-7
  14. Morris G et al. The role of inflammation in neuroimmune fatigue syndromes. Mol Neurobiol. 2015 Dec;52(3):1303-1316. https://doi.org/10.1007/s12035-015-9265-0
  15. Berman MH et al. Transcranial photobiomodulation improves cognitive performance in healthy young adults. Neurosci Med. 2017;8(4):414-422. https://doi.org/10.4236/nm.2017.84033
  16. Saltmarche AE et al. Significant cognitive improvement in Alzheimer’s patients with transcranial photobiomodulation. Photomed Laser Surg. 2017 Nov;35(11):632-639. https://doi.org/10.1089/pho.2017.4280
  17. Chao LL. Effects of home-based transcranial direct current stimulation (tDCS) on cognitive function in patients with mild cognitive impairment: a randomized controlled trial. J Alzheimers Dis. 2019;68(3):1015-1025. https://doi.org/10.3233/JAD-180875
  18. Lu Y et al. Near-infrared light reduces amyloid-beta levels in Alzheimer’s disease mouse model. Sci Rep. 2017 Nov 2;7(1):14871. https://doi.org/10.1038/s41598-017-14871-0
  19. Purushothuman S et al. Photobiomodulation mitigates amyloid-beta-induced neurotoxicity in primary hippocampal neurons. Alzheimers Res Ther. 2014 Sep 18;6(5):55. https://doi.org/10.1186/s13195-014-0055-5
  20. Mohammed HS et al. Photobiomodulation therapy improves neuronal survival in neurodegeneration models. Lasers Med Sci. 2017;32(6):1361-1371. https://doi.org/10.1007/s10103-017-2242-8
  21. Farivar S et al. Biological effects of low-level laser therapy. Lasers Med Sci. 2014 Mar;29(2):773-81. https://doi.org/10.1007/s10103-013-1399-5

Ready to find answers?

Stop surviving. Start recovering.

Similar Posts